<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04809402</url>
  </required_header>
  <id_info>
    <org_study_id>NL74625.041.20</org_study_id>
    <nct_id>NCT04809402</nct_id>
  </id_info>
  <brief_title>Cataract Online Refraction Evaluation: A Multi Center Randomized Controlled Trial</brief_title>
  <acronym>CORE-RCT</acronym>
  <official_title>Cataract Online Refraction Evaluation: A Multi Center Randomized Controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>UMC Utrecht</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Health Holland</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>UMC Utrecht</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Background of the study:&#xD;
&#xD;
      Cataract is widely prevalent in especially elderly and cataract extraction surgery has thus&#xD;
      become one of the most performedsurgeries worldwide. In recent decades the safety of cataract&#xD;
      surgery has greatly improved and it is considered one of the safestsurgeries to be performed.&#xD;
      Postoperative management consists of routine examinations within one week, to ascertain no&#xD;
      adverseevents have occurred immediately after surgery, and between 4-6 weeks, to determine&#xD;
      the refractive error. The incidence of seriousadverse events following cataract surgery is&#xD;
      estimated to be 1%. As a result, the majority of patient visits after cataract surgery willbe&#xD;
      uneventful. Nonetheless valuable time and hospital resources are consumed. Remote monitoring&#xD;
      could replace clinicalexaminations in selected patient groups. However, this practice of&#xD;
      digital remote monitoring which the patient can use independentlyhas not been clinically&#xD;
      validated yet.&#xD;
&#xD;
      Objective of the study:&#xD;
&#xD;
      To determine non-inferiority of the corrected distance visual acuity (CDVA) with the&#xD;
      prescription obtained through the web-basedmeasurement of refractive error, compared to usual&#xD;
      care, in patients who underwent routine cataract surgery.&#xD;
&#xD;
      Study design:&#xD;
&#xD;
      Observational randomized trial without interventions&#xD;
&#xD;
      Study population:&#xD;
&#xD;
      Patients eligible for cataract surgery, without visual acuity influencing comorbidities or&#xD;
      predisposing complicating factors.&#xD;
&#xD;
      Primary study parameters/outcome of the study:&#xD;
&#xD;
      costeffectiveness&#xD;
&#xD;
      Secundary study parameters/outcome of the study (if applicable):&#xD;
&#xD;
      Corrected distance visual acuity at the final post-operative visit, uncorrected distance&#xD;
      visual acuity, refractive error(sphere/cylinder/axes), patient reported outcome measurements,&#xD;
      adverse events.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 19, 2021</start_date>
  <completion_date type="Anticipated">April 5, 2023</completion_date>
  <primary_completion_date type="Anticipated">October 5, 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Cost-effectiveness</measure>
    <time_frame>pre-operative until 3 months after surgery</time_frame>
    <description>The main outcome measure will be Incremental cost-effectiveness ratio (ICER), defined as euros per QALY, and compared between the two groups.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Corrected distance visual acuity at the final post-operative visit (achieved with web-based vs manifest refraction)</measure>
    <time_frame>4-6 weeks after surgery</time_frame>
    <description>The corrected distance visual acuity achieved with the web-based refraction will be compared to the corrected distance visual acuity that is achieved with the subjective refraction.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Uncorrected distance visual acuity (web-based vs reference chart)</measure>
    <time_frame>pre-operative, 4-6 weeks after surgery</time_frame>
    <description>The uncorrected distance visual acuity that is assessed in the web-based assessment will be compared to the uncorrected distance visual acuity that is assessed using the reference chart.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Refractive error in sphere/cylinder/axes (web-based vs reference chart)</measure>
    <time_frame>4-6 weeks after surgery</time_frame>
    <description>The refractive error (in sphere/cylinder/axes) will be asssessed by the web-based assessment and compared to the subjective refractive error assessment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient reported outcomes</measure>
    <time_frame>pre-operative vs 3 months after surgery</time_frame>
    <description>The PROMs questionnaire (CatQuest-9SF) assesses the patient's own reported visual disability from cataract and the improvement after surgery. High scores represent better visual acuity. The results of the PROMs questionnaire will be compared between the groups to assess differences and determine if a web-based follow-up strategy influences these subjective measures. PROMs will be offered in Dutch, German or English accordingly and assessed at baseline and at 3 months follow-up.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse events / additional consultations</measure>
    <time_frame>pre-operative until 3 months after surgery</time_frame>
    <description>All unplanned additional consultations (telephone or hospital) will be recorded. We will count these and compare the frequencies between the two groups.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total costs</measure>
    <time_frame>pre-operative until 3 months after surgery</time_frame>
    <description>Total costs (in euros) will be determined for both groups. We will count costs for hospital resources and staff, as well as costs for the patient (such as travel and parking costs).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>QALY's</measure>
    <time_frame>pre-operative and 3 months after surgery</time_frame>
    <description>To determine the QALY, patients of both groups will be requested to fill out questionnaires to assess quality of life (EQ-5D). A unique health state is defined by combining one level from each of the five dimensions. Higher levels indicate more problems.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">94</enrollment>
  <condition>Cataract</condition>
  <arm_group>
    <arm_group_label>Telemonitoring</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Subjects in the telemonitoring group will have post-operative follow-up measurements involving teleconsultations, remote eye exams and health questionnaires.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Usual care</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Subjects in the usual care group will receive regular post-operative care, mostly involving in-hospital consultations.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>remote monitoring after cataract surgery</intervention_name>
    <description>remote monitoring after cataract surgery</description>
    <arm_group_label>Telemonitoring</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Planned for bilateral phacoemulsification cataract extraction and intra-ocular lens&#xD;
             implantation (either sequentialor in one procedure)&#xD;
&#xD;
          -  ≥ 18 years of age&#xD;
&#xD;
          -  No other current ophthalmic conditions or history that negatively influence&#xD;
             post-operative visual acuity&#xD;
&#xD;
          -  Be able to fill out the health questionnaires (in Dutch, German or English) and&#xD;
             perform the web-based refractiveassessment (possibly with assistance of family member&#xD;
             or other close relative).&#xD;
&#xD;
          -  Specific digital requirements include access to a computer and a smartphone and&#xD;
             knowledge how to log in to anonline patient portal.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Cataract extraction surgery combined with other procedures, including: keratoplasty,&#xD;
             vitrectomy, glaucoma filter implants&#xD;
&#xD;
          -  Ocular comorbidities that negatively influence post-operative visual acuity&#xD;
&#xD;
          -  No access to the digital requirements to take the online health questionnaire and/or&#xD;
             perform the online refraction.&#xD;
&#xD;
          -  Insufficient command of the Dutch, German or English language to understand the&#xD;
             questionnaires andinstructions of the web-based refractive assessment or no family&#xD;
             member / close relative to assist with this&#xD;
&#xD;
          -  Inability of performing the web-based eye exam prior to cataract surgery.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Vienna Institute for Research in Ocular Surgery, Austria</name>
      <address>
        <city>Vienna</city>
        <country>Austria</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Manuel Ruiss</last_name>
      <phone>+43 (0)1 91021- 57564</phone>
      <email>office@viros.at</email>
    </contact>
    <investigator>
      <last_name>Oliver Findl, MD, MBA, prof</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Josef Huemer, MD, FEBO</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Tübingen (Augenklink Sulzbach)</name>
      <address>
        <city>Sulzbach</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Kerstin Bessrich</last_name>
      <phone>+49 6897 574 3001</phone>
    </contact>
    <investigator>
      <last_name>Kai Januschowski, MD, apl. prof.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Augenklinik des Universitätsklinikums Ulm</name>
      <address>
        <city>Ulm</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Ursula Volk</last_name>
      <phone>+49 731 500-59222</phone>
    </contact>
    <investigator>
      <last_name>Armin Wolf, MD Prof</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Karsten Kortüm, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Maastricht UMC+</name>
      <address>
        <city>Maastricht</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Thomas Amelsfort, MD</last_name>
      <phone>+31 43 387 5137</phone>
      <email>thomas.van.amelsfort@mumc.nl</email>
    </contact>
    <investigator>
      <last_name>Thomas van Amelsfort, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Rudy Nuijts, MD PhD Prof</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Noel Bauer, MD PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Janneau Claessens</name>
      <address>
        <city>Utrecht</city>
        <zip>3508 GA</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Janneau Claessens, MD</last_name>
      <phone>+31887551683</phone>
      <email>j.l.j.claessens@umcutrecht.nl</email>
    </contact>
    <investigator>
      <last_name>Janneau Claessens, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Robert Wisse, MD PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Saskia Imhof, MD PhD Prof</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Austria</country>
    <country>Germany</country>
    <country>Netherlands</country>
  </location_countries>
  <verification_date>May 2021</verification_date>
  <study_first_submitted>March 10, 2021</study_first_submitted>
  <study_first_submitted_qc>March 18, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">March 22, 2021</study_first_posted>
  <last_update_submitted>May 7, 2021</last_update_submitted>
  <last_update_submitted_qc>May 7, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">May 10, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>UMC Utrecht</investigator_affiliation>
    <investigator_full_name>Robert P.L. Wisse, MD PhD</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>e-health</keyword>
  <keyword>digital</keyword>
  <keyword>remote monitoring</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cataract</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

